$CHRS
Coherus BioSciences Inc

2015 Q4 Form 10-K Financial Statement

#000156459016013726 Filed on February 29, 2016

View on sec.gov

Income Statement

Concept 2015 Q4 2015 2014 Q4
Revenue $10.20M $30.04M $6.493M
YoY Change 57.06% -3.42% 427.03%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $11.00M $36.00M $6.200M
YoY Change 77.42% 104.55% 148.0%
% of Gross Profit
Research & Development $51.40M $213.1M $26.90M
YoY Change 91.08% 172.37% 192.39%
% of Gross Profit
Depreciation & Amortization $600.0K $1.900M $300.0K
YoY Change 100.0% 181.9% 200.0%
% of Gross Profit
Operating Expenses $62.41M $249.1M $33.05M
YoY Change 88.8% 160.06% 182.05%
Operating Profit -$219.1M
YoY Change 238.68%
Interest Expense $0.00 $33.00K $0.00
YoY Change -99.15% -100.0%
% of Operating Profit
Other Income/Expense, Net -$400.0K -$4.838M -$2.500M
YoY Change -84.0% -73.98% 212.5%
Pretax Income -$52.60M -$223.9M -$29.00M
YoY Change 81.38% 156.77% 98.63%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$52.39M -$223.3M -$29.13M
YoY Change 79.83% 156.23% 99.55%
Net Earnings / Revenue -513.74% -743.18% -448.7%
Basic Earnings Per Share
Diluted Earnings Per Share -$1.344M -$6.019M -$3.549M
COMMON SHARES
Basic Shares Outstanding 37.13M 33.26M
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q4 2015 2014 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $158.2M $158.2M $150.4M
YoY Change 5.19% 5.19% 279.8%
Cash & Equivalents $158.2M $158.2M $150.4M
Short-Term Investments
Other Short-Term Assets $2.797M $37.60M $2.276M
YoY Change 22.89% 53.47% -60.76%
Inventory
Prepaid Expenses $34.74M $20.49M
Receivables $1.560M $2.417M
Other Receivables
Total Short-Term Assets $197.4M $197.4M $179.1M
YoY Change 10.19% 10.22% 292.18%
LONG-TERM ASSETS
Property, Plant & Equipment $10.50M $10.50M $4.472M
YoY Change 134.88% 133.33% 156.57%
Goodwill $943.0K $943.0K
YoY Change 0.0%
Intangibles $2.620M $2.620M
YoY Change 0.0%
Long-Term Investments
YoY Change
Other Assets $146.0K $900.0K $50.00K
YoY Change 192.0% 800.0% 85.19%
Total Long-Term Assets $15.00M $15.00M $8.085M
YoY Change 85.5% 85.19% 356.78%
TOTAL ASSETS
Total Short-Term Assets $197.4M $197.4M $179.1M
Total Long-Term Assets $15.00M $15.00M $8.085M
Total Assets $212.4M $212.4M $187.2M
YoY Change 13.44% 13.46% 294.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $25.95M $25.90M $8.778M
YoY Change 195.6% 194.32% 165.84%
Accrued Expenses $24.13M $24.10M $11.23M
YoY Change 114.88% 115.18% 53.85%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $106.0M $106.0M $51.78M
YoY Change 104.74% 104.63% -3.57%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.702M $113.3M $347.0K
YoY Change 390.49% 64.92% 468.85%
Total Long-Term Liabilities $1.702M $113.3M $347.0K
YoY Change 390.49% 64.92% 468.85%
TOTAL LIABILITIES
Total Short-Term Liabilities $106.0M $106.0M $51.78M
Total Long-Term Liabilities $1.702M $113.3M $347.0K
Total Liabilities $219.3M $218.6M $120.5M
YoY Change 82.06% 81.56% 34.1%
SHAREHOLDERS EQUITY
Retained Earnings -$186.7M
YoY Change 87.49%
Common Stock $254.1M
YoY Change 10001.43%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$6.207M -$6.200M $66.80M
YoY Change
Total Liabilities & Shareholders Equity $212.4M $212.4M $187.2M
YoY Change 13.44% 13.46% 294.59%

Cashflow Statement

Concept 2015 Q4 2015 2014 Q4
OPERATING ACTIVITIES
Net Income -$52.39M -$223.3M -$29.13M
YoY Change 79.83% 156.23% 99.55%
Depreciation, Depletion And Amortization $600.0K $1.900M $300.0K
YoY Change 100.0% 181.9% 200.0%
Cash From Operating Activities $5.600M -$108.0M -$33.30M
YoY Change -116.82% 351.88% -766.0%
INVESTING ACTIVITIES
Capital Expenditures -$1.500M $6.164M -$400.0K
YoY Change 275.0% 116.36% 100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 -$800.0K $0.00
YoY Change -134.78%
Cash From Investing Activities -$1.400M -$6.900M -$500.0K
YoY Change 180.0% 1280.0% 150.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 300.0K 122.7M 83.80M
YoY Change -99.64% -9.78%
NET CHANGE
Cash From Operating Activities 5.600M -108.0M -33.30M
Cash From Investing Activities -1.400M -6.900M -500.0K
Cash From Financing Activities 300.0K 122.7M 83.80M
Net Change In Cash 4.500M 7.800M 50.00M
YoY Change -91.0% -93.01% 941.67%
FREE CASH FLOW
Cash From Operating Activities $5.600M -$108.0M -$33.30M
Capital Expenditures -$1.500M $6.164M -$400.0K
Free Cash Flow $7.100M -$114.2M -$32.90M
YoY Change -121.58% 326.8% -732.69%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015 us-gaap License And Services Revenue
LicenseAndServicesRevenue
30041000
CY2015 us-gaap Sales Revenue Net
SalesRevenueNet
30041000
CY2015 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-4838000
CY2015 us-gaap Profit Loss
ProfitLoss
-223938000
CY2015 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
124000
CY2015 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
36046000
CY2014Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
2997000
CY2014 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-87702000
CY2013 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-53635000
CY2015Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1702000
CY2015Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
193000
CY2014Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
52000
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
51783000
CY2014Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
347000
CY2015Q4 us-gaap Liabilities
Liabilities
219313000
CY2014Q4 us-gaap Liabilities
Liabilities
120464000
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
5710000
CY2014Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-525000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-186725000
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
212384000
CY2015Q4 us-gaap Minority Interest
MinorityInterest
-722000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
-6207000
CY2015Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-6929000
CY2014Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2620000
CY2014Q4 us-gaap Goodwill
Goodwill
943000
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
24133000
CY2015Q4 chrs Collaboration Agreement Contingent Liability Noncurrent
CollaborationAgreementContingentLiabilityNoncurrent
66255000
CY2014Q4 chrs Collaboration Agreement Contingent Liability Noncurrent
CollaborationAgreementContingentLiabilityNoncurrent
27650000
CY2014Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
785000
CY2014 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
78224000
CY2015Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
45338000
CY2015Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
34743000
CY2015Q4 us-gaap Other Assets Current
OtherAssetsCurrent
2797000
CY2015Q4 us-gaap Goodwill
Goodwill
943000
CY2015Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
785000
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
146000
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
50000
CY2015Q4 us-gaap Assets
Assets
212384000
CY2014Q4 us-gaap Assets
Assets
187221000
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
25948000
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
8778000
CY2015Q4 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
3548000
CY2014Q4 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
2020000
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11231000
CY2015Q4 chrs Advance Payments Under License Agreement
AdvancePaymentsUnderLicenseAgreement
1330000
CY2014Q4 chrs Advance Payments Under License Agreement
AdvancePaymentsUnderLicenseAgreement
1192000
CY2015Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
49621000
CY2014Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
22800000
CY2015Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
1245000
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
106018000
CY2014Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
39899000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
66801000
CY2014Q4 us-gaap Minority Interest
MinorityInterest
-44000
CY2014Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
66757000
CY2014 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
2687000
CY2014 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-525000
CY2013 us-gaap Operating Expenses
OperatingExpenses
38744000
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
187221000
CY2015Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
6122000
CY2014 us-gaap Operating Expenses
OperatingExpenses
95788000
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
-64682000
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
-35993000
CY2014 us-gaap Interest Expense
InterestExpense
3900000
CY2015 us-gaap Interest Expense
InterestExpense
33000
CY2013 us-gaap Interest Expense
InterestExpense
5293000
CY2014 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-18595000
CY2013 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-12349000
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39005589
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39005589
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
33257978
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
33257978
CY2014 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
732000
CY2014 us-gaap Sales Revenue Net
SalesRevenueNet
31106000
CY2013 us-gaap Sales Revenue Net
SalesRevenueNet
2751000
CY2013 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
31279000
CY2014 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17564000
CY2013 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7465000
CY2014 us-gaap Profit Loss
ProfitLoss
-87177000
CY2013 us-gaap Profit Loss
ProfitLoss
-53635000
CY2014 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-44000
CY2012Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-45503000
CY2013 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6000
CY2013 chrs Adjustments To Additional Paid In Capital Vesting Of Restricted Stock Awards
AdjustmentsToAdditionalPaidInCapitalVestingOfRestrictedStockAwards
10000
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2045000
CY2013Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-97077000
CY2014 chrs Adjustments To Additional Paid In Capital Convertible Debt With Beneficial Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithBeneficialConversionFeature
-3939000
CY2014 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
48000
CY2014 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
55000
CY2014 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
2000
CY2014 chrs Adjustments To Additional Paid In Capital Vesting Of Restricted Stock Awards
AdjustmentsToAdditionalPaidInCapitalVestingOfRestrictedStockAwards
5000
CY2014 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11117000
CY2014 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
44000
CY2015 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1429000
CY2015 chrs Adjustments To Additional Paid In Capital Vesting Of Restricted Stock Awards
AdjustmentsToAdditionalPaidInCapitalVestingOfRestrictedStockAwards
9000
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
16712000
CY2015 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
678000
CY2015 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1869000
CY2014 us-gaap Depreciation And Amortization
DepreciationAndAmortization
674000
CY2013 us-gaap Depreciation And Amortization
DepreciationAndAmortization
404000
CY2015 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
4599000
CY2014 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
5185000
CY2014 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
15899000
CY2013 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
4557000
CY2013 chrs Fair Value Of Warrants In Excess Of Debt Proceeds Recognized At Issuance
FairValueOfWarrantsInExcessOfDebtProceedsRecognizedAtIssuance
3669000
CY2013 chrs Fair Value Of Embedded Derivatives In Excess Of Debt Proceeds Recognized At Issuance
FairValueOfEmbeddedDerivativesInExcessOfDebtProceedsRecognizedAtIssuance
4096000
CY2014 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
147000
CY2013 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
7579000
CY2015 chrs Noncash Interest Income Expense And Amortization
NoncashInterestIncomeExpenseAndAmortization
38000
CY2014 chrs Noncash Interest Income Expense And Amortization
NoncashInterestIncomeExpenseAndAmortization
-3897000
CY2013 chrs Noncash Interest Income Expense And Amortization
NoncashInterestIncomeExpenseAndAmortization
-5293000
CY2014 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
2048000
CY2015 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
382000
CY2015 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1300000
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
16721000
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
11062000
CY2015 us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
559000
CY2013 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
4026000
CY2014 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
299000
CY2013 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
56000
CY2014 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-23927000
CY2013 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
15423000
CY2014 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2849000
CY2013 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
373000
CY2014 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-525000
CY2013 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-373000
CY2015 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-678000
CY2014 us-gaap Net Income Loss
NetIncomeLoss
-87133000
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-53635000
CY2013 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-16.10
CY2014 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3629000
CY2015 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
1528000
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
2045000
CY2015 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-857000
CY2014 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2139000
CY2013 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
120000
CY2015 us-gaap Increase Decrease In Notes Receivable Current
IncreaseDecreaseInNotesReceivableCurrent
-1853000
CY2014 us-gaap Increase Decrease In Notes Receivable Current
IncreaseDecreaseInNotesReceivableCurrent
1815000
CY2014 us-gaap Increase Decrease In Notes Receivable Related Parties Current
IncreaseDecreaseInNotesReceivableRelatedPartiesCurrent
-107000
CY2013 us-gaap Increase Decrease In Notes Receivable Related Parties Current
IncreaseDecreaseInNotesReceivableRelatedPartiesCurrent
-16000
CY2015 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
14288000
CY2014 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
14692000
CY2013 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
3284000
CY2015 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
3329000
CY2014 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
2046000
CY2013 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-60000
CY2015 us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
-1691000
CY2014 us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
1691000
CY2015 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-42000
CY2014 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
25000
CY2013 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
21000
CY2015 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
18404000
CY2013 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
924000
CY2014 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
1637000
CY2013 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
-1310000
CY2015 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
12832000
CY2014 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3949000
CY2013 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2847000
CY2015 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-28000
CY2014 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
31000
CY2013 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-2000
CY2015 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
32294000
CY2014 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
19848000
CY2013 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
34749000
CY2015 chrs Increase Decrease In Advance Payments Under License Agreement
IncreaseDecreaseInAdvancePaymentsUnderLicenseAgreement
138000
CY2014 chrs Increase Decrease In Advance Payments Under License Agreement
IncreaseDecreaseInAdvancePaymentsUnderLicenseAgreement
1192000
CY2015 chrs Increase Decrease In Contingent Liability To Collaborator
IncreaseDecreaseInContingentLiabilityToCollaborator
38605000
CY2014 chrs Increase Decrease In Contingent Liability To Collaborator
IncreaseDecreaseInContingentLiabilityToCollaborator
20150000
CY2013 chrs Increase Decrease In Contingent Liability To Collaborator
IncreaseDecreaseInContingentLiabilityToCollaborator
7500000
CY2015 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
516000
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-107990000
CY2014 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
2334000
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6164000
CY2015 us-gaap Increase In Restricted Cash
IncreaseInRestrictedCash
785000
CY2014 us-gaap Increase In Restricted Cash
IncreaseInRestrictedCash
10000
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-6949000
CY2014 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
54660000
CY2013 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
2900000
CY2013 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
7050000
CY2014 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
131000
CY2014 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
85419000
CY2015 chrs Proceeds From Issuance Follow On Offering Net Of Underwriters Discounts And Commissions
ProceedsFromIssuanceFollowOnOfferingNetOfUnderwritersDiscountsAndCommissions
112800000
CY2015 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
10000000
CY2015 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1429000
CY2014 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
55000
CY2013 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
6000
CY2014 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
2000
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
122689000
CY2014 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
135956000
CY2013 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
9956000
CY2015 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
84000
CY2014 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-666000
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
7834000
CY2015 chrs Noncash Vesting Of Restricted Common Stock
NoncashVestingOfRestrictedCommonStock
9000
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
110838000
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
25006000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
39554000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14548000
CY2014 chrs Non Cash Contingent Consideration Related To Acquisition
NonCashContingentConsiderationRelatedToAcquisition
1310000
CY2014 chrs Convertible Preferred Stock Warrants Reclassified To Preferred Stock
ConvertiblePreferredStockWarrantsReclassifiedToPreferredStock
40150000
CY2014 chrs Noncash Vesting Of Restricted Common Stock
NoncashVestingOfRestrictedCommonStock
5000
CY2013 chrs Noncash Vesting Of Restricted Common Stock
NoncashVestingOfRestrictedCommonStock
10000
CY2015 chrs Purchases Of Property And Equipment Included In Accounts Payable And Accrued Liabilities
PurchasesOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities
1684000
CY2014 chrs Purchases Of Property And Equipment Included In Accounts Payable And Accrued Liabilities
PurchasesOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities
726000
CY2013 chrs Purchases Of Property And Equipment Included In Accounts Payable And Accrued Liabilities
PurchasesOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities
169000
CY2015 chrs Leasehold Improvements Allowance From Landlord
LeaseholdImprovementsAllowanceFromLandlord
1239000
CY2014 chrs Initial Public Offering Costs Included In Accounts Payable
InitialPublicOfferingCostsIncludedInAccountsPayable
855000
CY2015 chrs Costs Related To Future Offerings Included In Accounts Payable And Accrued Liabilities
CostsRelatedToFutureOfferingsIncludedInAccountsPayableAndAccruedLiabilities
124000
CY2014 chrs Accrued Expenses Settled With Common Stock Warrants
AccruedExpensesSettledWithCommonStockWarrants
55000
CY2014 chrs Accrued Expenses Settled With Preferred Stock
AccruedExpensesSettledWithPreferredStock
10000
CY2015 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
9849000
CY2015 us-gaap Nature Of Operations
NatureOfOperations
<div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Organization and Operations </p></td></tr></table></div> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description of the Business </p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is a late-stage clinical biologics platform company, focused on the global biosimilar market. The Company&#8217;s headquarters and laboratories are located in Redwood City, California and in Camarillo, California, respectively. The Company operates in one segment. </p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s clinical stage pipeline consists of a long-acting form of granulocyte colony-stimulating factor (&#8220;G-CSF&#8221;), and two anti-inflammatory agents targeting tumor necrosis factor (&#8220;TNF&#8221;): </p> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;;font-family:'Symbol';font-size:10pt;">&#183;</p></td> <td valign="top"> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s long-acting G-CSF product candidate, CHS-1701, is being developed as a pegfilgrastim (Neulasta) biosimilar. In October 2015, the Company has completed a pivotal pharmacokinetic (PK) and pharmacodynamics (PD) study for CHS-1701 in the United States (U.S.). Although it did not meet the PK AUC bioequivalence endpoint due to low, anomalous PK profile in the first period Neulasta group, the Company believes this study will support the planned filing of a biologics license application (BLA) in the U.S. as it met all the other co-primary endpoints including the PD endpoints. An immunogenicity study in healthy volunteers pursuant to this BLA met its primary endpoints. In February 2016, the Company initiated a follow-on PK/PD study, which is expected to read-out late in the first half of 2016. The Company expects to file a BLA in the United States directly thereafter.</p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;;font-family:'Symbol';font-size:10pt;">&#183;</p></td> <td valign="top"> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s most clinically advanced anti-TNF product candidate, CHS-0214, is being developed as an etanercept (Enbrel) biosimilar that the Company has partnered with Baxalta Incorporated, Baxalta US Inc., and Baxalta GmbH, (collectively &#8220;Baxalta&#8221;) and Daiichi Sankyo Company, Limited (&#8220;Daiichi Sankyo&#8221;) to develop and commercialize in key markets outside of the U.S. In October 2015, the Company completed part 1 of a Phase 3 clinical study in psoriasis comparing CHS-0214 to Enbrel.&nbsp;&nbsp;The Company is currently conducting a Phase 3 clinical study in rheumatoid arthritis. This study met the primary endpoint at 24 weeks. The Company expects that results from these studies, combined with data from its Phase 1 studies will support the expected filing of a marketing application in Europe and Japan in 2016.&nbsp;&nbsp;The Company has retained the development and commercial rights to this product in the U.S. However, the therapeutic protein in etanercept is subject to certain originator-controlled U.S. patents expiring in 2028 and 2029. Assuming these patents are valid and enforceable, and that the Company would be unable to obtain a license to them, the Company does not expect to commercialize CHS-0214 in the U.S. prior to their expiration.</p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;;font-family:'Symbol';font-size:10pt;">&#183;</p></td> <td valign="top"> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s second anti-TNF product candidate, CHS-1420, is being developed as an adalimumab (Humira) biosimilar. This product successfully completed a pivotal Phase 1 PK study in August 2014 by meeting the primary PK bioequivalence endpoint. The Company initiated a Phase 3 study in psoriasis in August 2015 to support the planned filing of a marketing application in the U.S. in 2016 and the E.U. in 2017. The Company initiated a bridging PK study comparing the Phase 3 CHS-1420 material to U.S. manufactured adalimumab (Humira) during the first quarter of 2016 and&nbsp;&nbsp;the Company plans to initiate a bridging PK study comparing the Phase 3 CHS-1420 material to E.U. manufactured adalimumab (Humira) in mid-2016.</p></td></tr></table></div> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Need to Raise Additional Capital </p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2015, the Company had an accumulated deficit of $410.0 million and cash and cash equivalents of $158.2&#160;million. <font style="color:#000000;">In February 2016,</font><font style="color:#000000;font-size:8pt;"> </font><font style="color:#000000;">we</font><font style="color:#000000;font-size:8pt;"> issued and </font><font style="color:#000000;">sold $100.0 million aggregate principal amount of 8.2% senior convertible notes (&#8220;Notes&#8221;) due March 31, 2022 (see Note 16).</font> The Company believes that its current available cash and cash equivalents, together with proceeds from the issuance of the Notes and funding it expects to receive under its license agreements with Daiichi Sankyo and Baxalta, will be sufficient to fund its planned expenditures under its 2016 budget and meet the Company&#8217;s obligations through at least December 31, 2016<font style="color:#1F497D;">. </font>The Company will need to raise additional funds in the future, however there can be no assurance that such efforts will be successful or that, in the event that they are successful, the terms and conditions of such financing will be favorable. If the Company is unable to obtain adequate financing when needed, it may have to delay, reduce the scope of or suspend one or more of its clinical trials, research and development programs or commercialization efforts.<font style="font-family:EYInterstate Light;">&nbsp;&nbsp;</font></p></div>
CY2015 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Reclassification</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">To maintain comparability among the periods presented, the Company reclassified certain prior period amounts to a separate line item that was not included in the prior period presentation. Within Note 4, Accrued Liabilities, in the Notes to the Consolidated Financial Statements for the year ended December 31, 2014, the Company reclassified amounts that were recorded within accrued other to accrued clinical and manufacturing. The reclassification had no impact on the total current accrued liabilities for the periods presented.</p></div>
CY2015 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. Management uses significant judgment when making estimates related to its stock-based compensation, valuation of deferred tax assets, impairment of goodwill and long-lived assets, the valuation of acquired intangible assets, clinical trial accruals, revenue recognition period, as well as certain accrued liabilities; and in prior years, common stock valuation, the valuations of the convertible preferred stock warrant liability and embedded derivative instruments. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates.&nbsp;&nbsp;</p></div>
CY2015 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk </p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The Company&#8217;s financial instruments that are exposed to concentration of credit risk consist primarily of cash and cash equivalents. The Company maintains its cash in bank accounts which at times exceed federally insured limits. The Company attempts to minimize the<font style="font-family:inherit;"> risks related to cash and cash equivalents by investing in money markets with a broad and diverse range of financial instruments. The investment portfolio is maintained in accordance with the Company&#8217;s investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. </font>The Company also maintains restricted cash in money market funds that invest primarily in U.S. Treasury securities. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on its cash and money market funds. </p></div>
CY2015 us-gaap Derivatives Embedded Derivatives
DerivativesEmbeddedDerivatives
<div> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Embedded Derivative Liability </p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The Company recorded derivative instruments related to redemption features embedded within the convertible notes when such notes were outstanding. The embedded derivatives were accounted for as a liability and were remeasured to fair value as of each balance sheet date when such notes were outstanding, with the related remeasurement adjustment being recognized as a component of other income (expense), net in the consolidated statements of operations. </p></div>
CY2015 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2015 us-gaap Foreign Currency Transaction Loss Before Tax
ForeignCurrencyTransactionLossBeforeTax
386000
CY2013 us-gaap Foreign Currency Transaction Loss Before Tax
ForeignCurrencyTransactionLossBeforeTax
34000
CY2014 us-gaap Foreign Currency Transaction Gain Before Tax
ForeignCurrencyTransactionGainBeforeTax
671000
CY2015 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2015Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
137000
CY2014Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
0
CY2015 us-gaap Income Tax Examination Likelihood Of Unfavorable Settlement
IncomeTaxExaminationLikelihoodOfUnfavorableSettlement
less than a 50%
CY2015Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2014Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2015 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Into Level3
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersIntoLevel3
0
CY2014 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Into Level3
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersIntoLevel3
0
CY2015 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Out Of Level3
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersOutOfLevel3
0
CY2014 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Out Of Level3
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersOutOfLevel3
0
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
14024000
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5764000
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3520000
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1292000
CY2015Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
3100000
CY2015Q4 chrs Accrued Clinical And Manufacturing Liabilities Current
AccruedClinicalAndManufacturingLiabilitiesCurrent
11681000
CY2014Q4 chrs Accrued Clinical And Manufacturing Liabilities Current
AccruedClinicalAndManufacturingLiabilitiesCurrent
2396000
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4666000
CY2014Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3435000
CY2015Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
446000
CY2014Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
252000
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1218000
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2151000
CY2014 us-gaap License And Services Revenue
LicenseAndServicesRevenue
30374000
CY2013 us-gaap License And Services Revenue
LicenseAndServicesRevenue
2751000
CY2014Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
2335000
CY2014Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Prepaid Expense And Other Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
107000
CY2014Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities
1027000
CY2014Q4 chrs Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed In Process Research And Development
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment
2620000
CY2014Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net
BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
4978000
CY2015Q4 chrs Number Of Contingent Consideration For Potential Payments
NumberOfContingentConsiderationForPotentialPayments
2
CY2015 chrs Contingent Consideration Probability Of Completion
ContingentConsiderationProbabilityOfCompletion
0.75
CY2015 chrs Fair Value Inputs Contingent Probability
FairValueInputsContingentProbability
0.075
CY2014Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
6500000
CY2013Q4 chrs Reduced Derivative Liability
ReducedDerivativeLiability
0
CY2014 us-gaap Interest Expense Debt
InterestExpenseDebt
3900000
CY2013 us-gaap Interest Expense Debt
InterestExpenseDebt
4800000
CY2015 chrs Lease Initiation Date
LeaseInitiationDate
2011-09-26
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
1692000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
1276000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
1669000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
1719000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
5315000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
11671000
CY2015 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1800000
CY2014 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
800000
CY2013 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
400000
CY2014 chrs Net Change In Fair Value Of Convertible Preferred Stock Warrant Liability
NetChangeInFairValueOfConvertiblePreferredStockWarrantLiability
15900000
CY2013 chrs Net Change In Fair Value Of Convertible Preferred Stock Warrant Liability
NetChangeInFairValueOfConvertiblePreferredStockWarrantLiability
8900000
CY2014Q1 chrs Common Stock Warrant Fair Value Per Share
CommonStockWarrantFairValuePerShare
5.73
CY2014Q4 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
21316519
CY2014Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
1
CY2014Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2652500
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
1330319
CY2015 chrs Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Granted At Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAtFairValue
3217313
CY2015 chrs Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Forfeited
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesForfeited
317641
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1083147
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5770307
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3217313
CY2015 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
861137
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
317641
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7808842
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.909
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
28.020
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.660
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
15.066
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.898
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
7747817
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
3054854
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
12.839
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
4.956
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y3M7D
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y3M4D
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P7Y4M2D
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
94220000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
93860000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
56696000
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y6M
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y6M4D
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.78
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.99
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.08
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0162
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0205
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0123
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend
0
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
14600000
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
4200000
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
0
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
18.42
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.65
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.88
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1400000
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
400000
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2015Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
55200000
CY2015 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y1M24D
CY2015 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.3400
CY2014 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.3400
CY2013 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.3400
CY2015 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0070
CY2014 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.0165
CY2013 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0397
CY2015 chrs Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
-0.0125
CY2014 chrs Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
-0.1080
CY2013 chrs Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
-0.1240
CY2015 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.0246
CY2014 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.0311
CY2013 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.0453
CY2015 chrs Effective Income Tax Rate Reconciliation Net Operating Loss
EffectiveIncomeTaxRateReconciliationNetOperatingLoss
-0.0001
CY2014 chrs Effective Income Tax Rate Reconciliation Net Operating Loss
EffectiveIncomeTaxRateReconciliationNetOperatingLoss
0.0001
CY2014 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Investment
EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment
0.0073
CY2015 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.0009
CY2014 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.0002
CY2015 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.3599
CY2014 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.2542
CY2013 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.3010
CY2015 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00
CY2014 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00
CY2013 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
91334000
CY2014Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
34463000
CY2015Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
12980000
CY2014Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
6032000
CY2015Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
778000
CY2014Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
854000
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
5111000
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1428000
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
2236000
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
940000
CY2015Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
23237000
CY2014Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
12762000
CY2015Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
135676000
CY2013 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4828214
CY2015 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
3609
CY2014Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
56479000
CY2015Q4 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
891000
CY2014Q4 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
892000
CY2015Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
891000
CY2014Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
892000
CY2015Q4 chrs Deferred Tax Asset Liability Net
DeferredTaxAssetLiabilityNet
134785000
CY2014Q4 chrs Deferred Tax Asset Liability Net
DeferredTaxAssetLiabilityNet
55587000
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
134785000
CY2014Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
55587000
CY2015Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2014Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2015 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
79200000
CY2014 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
22100000
CY2013 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
16100000
CY2015Q4 chrs Operating Loss Carryforward Future Equity Effect Of Unrecognized Tax Benefits From Stock Options Exercised
OperatingLossCarryforwardFutureEquityEffectOfUnrecognizedTaxBenefitsFromStockOptionsExercised
7400000
CY2014Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
3816000
CY2013Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
749000
CY2012Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
73000
CY2015 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
3633000
CY2014 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
861000
CY2013 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
319000
CY2015 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
3156000
CY2014 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
2206000
CY2013 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
357000
CY2015Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
10605000
CY2015 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2014 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2013 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2015 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37125617
CY2014 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8520100
CY2014 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
333571
CY2013 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
1496194
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7808842
CY2014 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5770307
CY2013 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16839946
CY2011Q4 chrs Number Of Founders Entered Into Agreement
NumberOfFoundersEnteredIntoAgreement
4
CY2015Q1 us-gaap Sales Revenue Net
SalesRevenueNet
5810000
CY2015Q2 us-gaap Sales Revenue Net
SalesRevenueNet
6866000
CY2015Q3 us-gaap Sales Revenue Net
SalesRevenueNet
7167000
CY2015Q4 us-gaap Sales Revenue Net
SalesRevenueNet
10198000
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
42558000
CY2015Q2 us-gaap Operating Expenses
OperatingExpenses
65761000
CY2015Q3 us-gaap Operating Expenses
OperatingExpenses
78384000
CY2015Q4 us-gaap Operating Expenses
OperatingExpenses
62405000
CY2015Q1 us-gaap Profit Loss
ProfitLoss
-40839000
CY2015Q2 us-gaap Profit Loss
ProfitLoss
-59034000
CY2015Q3 us-gaap Profit Loss
ProfitLoss
-71485000
CY2015Q4 us-gaap Profit Loss
ProfitLoss
-52580000
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-40725000
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-58810000
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-71334000
CY2015Q4 us-gaap Net Income Loss
NetIncomeLoss
-52391000
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.22
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.56
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.86
CY2015Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.35
CY2014Q1 us-gaap Sales Revenue Net
SalesRevenueNet
3596000
CY2014Q2 us-gaap Sales Revenue Net
SalesRevenueNet
4965000
CY2014Q3 us-gaap Sales Revenue Net
SalesRevenueNet
16052000
CY2014Q4 us-gaap Sales Revenue Net
SalesRevenueNet
6493000
CY2014Q1 us-gaap Operating Expenses
OperatingExpenses
17357000
CY2014Q2 us-gaap Operating Expenses
OperatingExpenses
22903000
CY2014Q3 us-gaap Operating Expenses
OperatingExpenses
22475000
CY2014Q4 us-gaap Operating Expenses
OperatingExpenses
33053000
CY2014Q1 us-gaap Profit Loss
ProfitLoss
-25170000
CY2014Q2 us-gaap Profit Loss
ProfitLoss
-25070000
CY2014Q3 us-gaap Profit Loss
ProfitLoss
-7914000
CY2014Q4 us-gaap Profit Loss
ProfitLoss
-29023000
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-25170000
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-24957000
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-7872000
CY2014Q4 us-gaap Net Income Loss
NetIncomeLoss
-29134000
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-6.04
CY2014Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.96
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.79
CY2014Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.47

Files In Submission

Name View Source Status
0001564590-16-013726-index-headers.html Edgar Link pending
0001564590-16-013726-index.html Edgar Link pending
0001564590-16-013726.txt Edgar Link pending
0001564590-16-013726-xbrl.zip Edgar Link pending
chrs-10k_20151231.htm Edgar Link pending
chrs-20151231.xml Edgar Link completed
chrs-20151231.xsd Edgar Link pending
chrs-20151231_cal.xml Edgar Link unprocessable
chrs-20151231_def.xml Edgar Link unprocessable
chrs-20151231_lab.xml Edgar Link unprocessable
chrs-20151231_pre.xml Edgar Link unprocessable
chrs-ex231_9.htm Edgar Link pending
chrs-ex311_6.htm Edgar Link pending
chrs-ex312_7.htm Edgar Link pending
chrs-ex321_8.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g20160229195813944873.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending